Insights into the Mechanism of Ethionamide Resistance in <em>Mycobacterium tuberculosis</em> through an <em>in silico</em> Structural Evaluation of EthA and Mutants Identified in Clinical Isolates

Abstract

Mutation in the ethionamide (ETH) activating enzyme, EthA, is the main factor determining resistance to this drug, used to treat TB patients infected with MDR and XDR Mycobacterium tuberculosis isolates. Many mutations in EthA of ETH resistant (ETH-R) isolates have been described but their roles in resistance remain uncharacterized, partly because structural studies on the enzyme are lacking. Thus, we took a two-tier approach to evaluate two mutations (Y50C and T453I) found in ETH-R clinical isolates. First, we used a combination of comparative modeling, molecular docking, and molecular dynamics to build an EthA model in complex with ETH that has hallmark features of structurally characterized homologs. Second, we used free energy computational calculations for the reliable prediction of relative free energies between the wild type and mutant enzymes. The &amp;Delta;&amp;Delta;G values for Y50C and T453I mutant enzymes in complex with FADH2-NADP-ETH were 3.34 (+/&amp;minus;0.55) and 8.11 (+/&amp;minus;0.51) kcal/mol, respectively, compared to the wild type complex. The positive &amp;Delta;&amp;Delta;G values indicate that the wild type complex is more stable than the mutants, with the T453I complex being the least stable. These are the first results shedding light on the molecular basis of ETH resistance, namely reduced complex stability of mutant EthA.